Edition:
United Kingdom

CSPC Pharmaceutical Group Ltd (1093.HK)

1093.HK on Hong Kong Stock

23.80HKD
21 May 2018
Change (% chg)

HK$0.05 (+0.21%)
Prev Close
HK$23.75
Open
HK$23.65
Day's High
HK$23.95
Day's Low
HK$23.40
Volume
35,917,539
Avg. Vol
28,387,050
52-wk High
HK$23.95
52-wk Low
HK$10.94

Chart for

About

CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and... (more)

Overall

Beta: 0.72
Market Cap(Mil.): HK$148,271.70
Shares Outstanding(Mil.): 6,243.02
Dividend: 0.15
Yield (%): 0.63

Financials

  1093.HK Industry Sector
P/E (TTM): 52.23 28.57 32.53
EPS (TTM): 0.45 -- --
ROI: 21.15 13.08 12.63
ROE: 21.79 14.80 14.50

BRIEF-CSPC Pharmaceutical Announces A Product Licensing Agreement

* UNIT ENTERED PRODUCT LICENSING AGREEMENT WITH GALAXY BIO, INC. FOR LICENSING & COMMERCIALIZATION OF "PACLITAXEL FOR INJECTION"

18 Apr 2018

BRIEF-CSPC Pharmaceutical Group Says Cancer Drug Approved By China FDA

* "VINORELBINE TARTRATE LIPOSOME INJECTION" GRANTED CLINICAL TRIAL APPROVAL BY CHINA FOOD AND DRUG ADMINISTRATION OF PRC Source text for Eikon: Further company coverage:

16 Apr 2018

BRIEF-CSPC Pharmaceutical Group's Drug Gets Approval By China FDA

* GRANTED APPROVAL BY CHINA FDA FOR PASSING CONSISTENCY OF QUALITY AND EFFICACY EVALUATION OF GENERIC DRUGS

12 Apr 2018

BRIEF-CSPC Pharmaceutical Group Says ‍Cancer Drug Granted Drug Clinical Trial Approval By China FDA

* ‍CANCER DRUG DEVELOPED BY WUHAN YZY BIOPHARMA​ GRANTED DRUG CLINICAL TRIAL APPROVAL BY CHINA FDA Source text for Eikon: Further company coverage:

16 Mar 2018

BRIEF-CSPC Pharmaceutical Group Announces Drug Registration Approval Of "Paclitaxel For Injection (Albumin-Bound)"

* ‍"PACLITAXEL FOR INJECTION (ALBUMIN-BOUND)" GRANTED DRUG REGISTRATION APPROVAL BY CHINA FOOD AND DRUG ADMINISTRATION Source text for Eikon: Further company coverage:

12 Feb 2018

BRIEF-CSPC Pharmaceutical Group's Gastric Cancer Drug Granted Orphan-Drug Designation By U.S. FDA​

* ‍GROUP'S GASTRIC CANCER DRUG "DP303C" WAS GRANTED ORPHAN-DRUG DESIGNATION BY U.S. FDA​ Source text for Eikon: Further company coverage:

06 Feb 2018

BRIEF-CSPC Pharmaceutical Group Says Unit's Listing Application To CSRC Was Accepted

* CSPC XNW SUBMITTED APPLICATION TO CSRC FOR PROPOSED A SHARE LISTING ON CHINEXT OF SZSE & RECEIVED NOTICE OF ACCEPTANCE

27 Dec 2017

BRIEF-CSPC Pharmaceutical Group Appoints ‍Li Chunlei As Executive Director ​

* ‍LI CHUNLEI WAS APPOINTED AS AN EXECUTIVE DIRECTOR OF COMPANY WITH EFFECT FROM 12 DECEMBER 2017.​

12 Dec 2017

Earnings vs. Estimates